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ZEB FACTORS IN ORAL SQUAMOUS CELL CARCINOMA 
Saira Ahmed 
March 26, 2017 
Objectives:  The ZEB family of transcription factors (ZEB1 and ZEB2) have been 
demonstrated to play a role in metastatic progression of several cancers, and may also 
influence the initial transformation and generation of cancer stem cells. However, the 
expression pattern of ZEB proteins in the development of oral squamous cell carcinoma 
has not been investigated.  The purpose of this study was to define changes in expression 
and subcellular localization of the ZEB family in both precancerous lesions and different 
grades of OSCC.   
Materials and Methods: Seventy-nine tongue biopsies were subjected to 
immunohistochemistry and immunofluorescence to determine the expression and 
subcellular location of ZEB1 and ZEB2 across six histological grades of precancerous 
and cancerous lesions.    
Results: Surprisingly, Both ZEB1 and ZEB2 exhibit changes in subcellular location 
between healthy tissue, dysplasia, carcinoma in situ, and well differentiated, moderately 
differentiated, and poorly differentiated carcinoma.  ZEB1 expression in healthy tissue is 
mainly nuclear.  As carcinoma progresses, subsets of patients show either primarily 
cytosolic or primarily nuclear ZEB1 in tumors.  In histologically normal tissue, ZEB2 is 
expressed in the cytosol of a band of suprabasal cells.  In early grades of carcinoma it 
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remains cytosolic, but in more advanced carcinoma becomes a mix of cells with either 
nuclear or cytosolic ZEB2.   
Conclusions: Changes of subcellular distribution of ZEB1 and ZEB2 occur during 
development of oral squamous cell carcinoma. Cytosolic localization of either ZEB1 or 
ZEB2 likely disrupts their ability to regulate transcription. The presence of patients with 
differences in ZEB1 or ZEB2 localization suggest that there may be different clinical 
outcomes related to different patterns of expression.
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 CHAPTER I 
INTRODUCTION 
OSCC Background 
Worldwide, oral squamous cell carcinoma (OSCC) remains one of the most 
prevalent cancers, with the yearly incidence being about 400,000 new cases diagnosed 
with over 200,000 deaths (Chaturvedi, Anderson et al. 2013).  The five year survival for 
OSCC is approximately 50%; importantly, this has remained the same for the past several 
decades (Warnakulasuriya 2009).  Furthermore, the treatment options for OSCC 
oftentimes result in reduced quality of life due to invasive surgical techniques.  OSCC is 
a subset of head and neck squamous cell carcinoma; it includes squamous cell 
carcinomas of the lip, tongue, and the oral cavity (Warnakulasuriya 2009).  Early stages 
of oral cancer may be cured by either surgery or radiation (Tsantoulis, Kastrinakis et al. 
2007).  More advanced cancers require surgery followed by subsequent radiation.  In the 
United States, OSCC is predominantly related to tobacco use (Vigneswaran and Williams 
2014).  Other risk factors include excessive alcohol consumption, bethel quid use, and the 
human papilloma virus (Warnakulasuriya 2009).  The best way to prevent OSCC is 
smoking cessation and reduction in alcohol consumption.   
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One other major risk factor that is associated with OSCC is the human papilloma 
virus (Tsantoulis, Kastrinakis et al. 2007).  Specifically, the HPV virus can interfere with 
the tumor suppressor p53 and subsequently blocks the downstream activity of pRb 
resulting in the interference with DNA replication and decreased normal apoptotic 
activity (Andrews, Seaman et al. 2009).  Impairment of the cell’s mechanisms to protect 
against aberrant growth allows tumor proliferation. (Remove?)   
OSCC is the sixth most common cancer worldwide, and commonly occurs in 
many Asian countries.  Generally, the incidence in men is two times as great as in 
women.  These numbers have been consistent in men between the years 2006-2010.  The 
incidence in women has decreased 0.9% annually from 2006-2010.  Oral squamous cell 
carcinoma associated with human papilloma virus has been increasing among white men 
and women.  The number of deaths expected from carcinoma of the oral cavity and 
pharynx in 2014 is 8,390.  Over the past three decades, death rates have been falling 
(American Cancer Society.).  The mortality rate is about 50% and has remained at this 
level for the past three decades.  One of the main reasons for this lies in the fact that 
OSCC is often difficult to diagnose until the caner has metastasized to distant organ sites.  
To date, there have not been any established protocols or diagnostic tools for the early 
detection of OSCC (Lingen, Kalmar et al.).  Currently, the standard of care is routine oral 
cancer screenings in at-risk populations, particularly in high-risk areas such as the floor 
of the mouth, the retromolar pad area, the tonsillar pillars, and the latero-ventral tongue.   
Another area of concern regarding OSCC is the fact that in many cases the 
carcinomas are initially responsive to treatments such as radiotherapy and chemotherapy, 
but relapse is common (Chen, Zimmermann et al. 2013).  Treatment relapse occurs both 
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at local and distant sites.  Thus, poor prognosis results from both metastatic disease and 
the recurrence of OSCC.  Often, recurrent disease is either inoperable or resistant to 
conventional therapy such as chemotherapy or radiation.  Mortality due to OSCC is 
frequently caused by cervical lymph node metastasis (Chu, Hu et al. 2013).   
 
Development of OSCC 
Carcinogenesis of the oral epithelium proceeds through a spectrum of precursor 
lesions that may progress to OSCC; including oral epithelial dysplasia (OED) and 
carcinoma in situ (CIS).  Clinically, OED most often presents as white, red or a mixture 
of white and red lesions (Brennan, Migliorati et al. 2007).  The white lesions are referred 
to as leukoplakia, the red ones as erythroplakia and the mixture as speckled leukoplakia.  
These lesions are characterized as surface lesions on the oral mucosa.  Within OED there 
are three different grades: mild, moderate, and severe.  Each of these grades is based 
upon the extent of histological deviation from normal epithelial tissue architecture and 
maturation.  Mild dysplasia shows aberrations to the lower one-third of the epithelium, 
moderate involves one-half, and severe through two-thirds of the epithelial thickness 
(Woolgar and Triantafyllou 2011).  When dysplastic changes become more pronounced 
and involve the whole thickness of the epithelium, the lesion is considered to be 
carcinoma in situ (CIS) (Kumar, Abbas et al. 2013).  CIS is not considered to be cancer; 
the distinction being that has not yet invaded the surrounding connective tissue.   
 Once CIS has invaded the adjacent connective tissue it may be classified as well-
differentiated, moderately differentiated or poorly differentiated carcinoma.  Well-
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differentiated carcinoma is characterized by the presence of keratin pearls which indicate 
a high degree of differentiation (Woolgar and Triantafyllou 2011).  Moderately 
differentiated carcinoma is characterized by the presence of abnormal keratinization.  
Poorly differentiated carcinoma is identified by highly irregular tissue architecture.   
 All cancers possess certain characteristics and oral carcinomas are not an 
exception.  These hallmarks include: evading apoptosis, self-sufficiency in growth 
signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative 
potential, and tissue invasion and metastasis (Hanahan and Weinberg 2000).  Invasion 
and metastasis are of growing concern in regards to OSCC because the majority of OSCC 
related deaths are related to primary tumors metastasizing to distant tissue sites, including 
lymph nodes and other organs (Chu, Hu et al. 2013).   
 Tumor cells become invasive by specific molecular mechanisms.  One such 
mechanism that has been implicated in tumor invasion is the epithelial to mesenchymal 
transition (EMT) (Chu, Hu et al. 2013).  This process allows cells to increase their 
invasiveness by undergoing changes in morphology, loss of polarity, and loss of cell to 
cell contacts (Chen, Zimmermann et al. 2013).  EMT is not exclusively a tumorigenic 
process—it is present during embryonic development and homeostatic processes such as 
wound healing.  EMT in cancer progression is induced by the TGF-β pathway via Smad 
signaling (Lamouille, Xu et al. 2014).   
 
Epithelial to mesenchymal transition (EMT) 
Epithelial tissue can be either one layer of or multiple layers (Lamouille, Xu et al. 
2014).  Cells of the epithelium communicate through intracellular junctions.  Since the 
5	
epithelium is highly specialized, it was previously thought that epithelial cells are 
inalterably programmed to retain their phenotype, but this is not the case (Kalluri and 
Neilson 2003).  Epithelial cells retain some degree of plasticity and are able to change 
their phenotype.  The process of epithelial cells undergoing changes to express a 
mesenchymal phenotype is termed epithelial-to-mesenchymal transition (EMT).  EMT is 
a mechanism used for forming fibroblasts in injured tissues and spreading cells in 
vertebrate embryos.  Furthermore, mature epithelium can undergo EMT in certain 
situations such as inflammation or wounding-healing that can lead to the production of 
fibroblasts and fibrogenesis (Vered, Dayan et al. 2010).    
The process of EMT leads to the disruption of the basement membrane; this 
process is aided by matrix metalloproteases or membrane assembly inhibitors (Kalluri 
and Neilson 2003).  Disruption of cell adhesion is observed in many cancers, it correlates 
with poor prognosis and metastasis (Comijn, Berx et al.).  Epithelial-cadherin (E-
cadherin), is an integral component of the epithelial junctional system.  It maintains cell-
cell adhesion, having an extracellular domain which binds adjacent cells, and links 
intracellularly through catenin to the actin cytoskeleton.  E-cadherin suppresses invasion 
by tumor cells.  Conversely, loss of E-cadherin results in increased invasion.   
EMT has been implicated in development, wound-healing, fibrosis, and cancer 
progression (Bronsert, Kohler et al. 2014).  It’s involvement with cancer is specifically 
with the process of metastasis.  EMT in cancer can lead to increased invasion and 
motility.  EMT of carcinoma cells has been linked to the acquisition of cancer stem cell 
traits such as resistance to chemotherapy and increased tumorgenicity, the reason for this 
being that once epithelial cells become more mesenchymal they also resist senescence 
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and apoptosis (Lamouille, Xu et al. 2014).  There are several transcription factors that 
have been implicated in driving EMT, including ZEB1, ZEB2, TWIST, and Slug (Chen, 
Zimmermann et al. 2013).  Since metastasis is a leading cause of mortality for patients 
with OSCC, the process and those transcription factors that govern it should be further 
analyzed.  EMT is a process that is temporary, whereby epithelial cells transiently 
become mesenchymal and can revert to the epithelial phenotype once they have 
populated other tissues (Lamouille, Xu et al. 2014).   
After epithelial cells undergo malignant transformation, they become more 
amorphous and the tissue itself becomes less organized.  While cells are undergoing these 
changes, cells also become detached from each other and therefore are not well-anchored. 
Claudin and other occluding proteins are down-regulated in order for tight junctions to be 
dissolved.  EMT drives the process of metastasis by allowing tumor cells to migrate away 
from the initial tumor location and circulate as circulating tumor cells (CTCs).   
One of the ways in which EMT is induced by the TGF-β pathway is via Smad 
signaling.  TGF-β is a family of cytokines that play roles in processes such as fibrosis and 
wound healing (Kalluri and Neilson 2003) (Chu, Hu et al. 2013).  It has been shown in 
cell culture studies that cells will adopt mesenchymal characteristics in the presence of 
the TGF-β, during this process, the transcription factors ZEB1, ZEB2, Snail, and Slug 
may also be upregulated (Gregory, Bracken et al. 2011).  EMT may also be induced via 
the Wnt/beta-catenin pathway; the disruption of this pathway has been demonstrated to 
influence tissue differentiation (Shiah, Shieh et al. 2016).    
In addition to changes in cell adhesion, the actual morphology of the cells changes 
during EMT (Lamouille, Xu et al. 2014).  The cytoskeleton undergoes changes that 
7	
enable the cell to become elongated.  The cell forms projections that allow it to promote 
movement.  The new membrane projections are actin-rich thereby conferring proteolytic 
function in the newly formed invadipodia.  Also during EMT, cells become more 
contractile due to the actin stress fiber formation.   
In EMT not only is E-cadherin down-regulated, there is a phenomenon known as 
a “cadherin-switch.” (Lamouille, Xu et al. 2014) In this process,  E-cadherin is 
downregulated,  the consequence of this being that the cells are allowed to become more 
invasive.  E-cadherin allows cells to be anchored in place.  Another change in gene 
expression also occurs in the cytoskeletal elements.  Cytokeratins are repressed while the 
expression of vimentin is enhanced.  Also during EMT, the extracellular matrix is being 
remodeled which then alters cell interactions.   
It has been shown experimentally that when ZEB2 binds at the two highly 
conserved E2 boxes within the E-cadherin promoter it represses the activity of the gene 
(Comijn, Berx et al.).  In this particular experiment, ZEB2 was co-transfected with 
reporter plasmids driven by the E-cadherin promoter in the E-cadherin positive cell line 
MDCK. ZEB2 caused an 80% decrease in the activity of the E-cadherin promoter.  
Mutation of either zinc finger domain resulted in less repression.  Furthermore, it was 
shown that in E-cadherin positive cells, E-cadherin expression can be repressed by 
exogenous ZEB2.  This repression of E-cadherin by ZEB2 is Snail independent.  
Interestingly, ZEB2 decreases cell adhesion, but does not increase cell migration.  The 
results for this particular study indicate that ZEB2 can directly repress E-cadherin.   
There have been some studies that show that the anti-diabetic drug Metformin can 
decrease the expression of EMT-inducing factors such as Slug, ZEB1, ZEB2, and Twist 
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(Chen, Zimmermann et al. 2013).  Theoretically, blocking transcription factors that 
induce EMT should be a favorable therapy, but before that may be done their exact roles 
should be understood.   
EMT is heavily influenced by both ZEB1 and ZEB2, but it is also regulated by 
microRNAs.  MicroRNAs (miRs) are small, non-coding single strands of RNA that can 
block protein synthesis by inhibiting mRNA translation or promoting its degradation; 
miRs can act by targeting the 3’ untranslated region (Sun, Zhang et al. 2014).  Mounting 
evidence shows that miRs can play a role in different processes such as cellular growth, 
differentiation, and development.  In melanoma and lung adenocarcinoma it has been 
shown that the miR-200 family inhibits EMT by repressing ZEB1 and ZEB2 expression 
(Chu, Hu et al. 2013).  In cell culture studies, it has been demonstrated that the miR-200 
family and miR-205 are downregulated in those cells that had undergone EMT (Gregory, 
Bert et al. 2008).  Conversely, those cells that were expressing microRNAs showed 
downregulation of EMT markers.  The way the miR-200 family inhibits EMT-activators 
is by inducing epithelial differentiation; they promote the epithelial phenotype (Wellner, 
Schubert et al. 2009).  It has been demonstrated that there is a double-feedback loop 
governing the expression of EMT factors and certain families of microRNAs.  For 
example, the ZEB family transcriptionally represses miR-200, but also miR-200 acts as a 
post-transcriptional repressor of ZEB factors (Brabletz and Brabletz 2010).  This, 
however, is not acting alone.  There is also interplay with another pair, the miR-34/Snail, 
loop that is also influencing gene expression (Lu, Jolly et al. 2013).  Along with ZEB 
factors, Snail also represses the miR-200 as well as miR-34.  Both ZEB1 and ZEB2 are 
influencing the expression of both micro-RNAs, but both microRNAs are not influencing 
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both.  In other words, only miR-34 is affecting Snail while only miR-200 is affecting 
ZEB.   
Overall, there are many potential therapeutic targets with regards to EMT, 
however, different cancers are driven by different players such as ZEBs, Snails, Wnts, 
TGFs, micro RNAs, etc.  An improved understanding of EMT in OSCC is needed in 
order to effectively block EMT (Chen, Zimmermann et al. 2013).   
 
ZEB Family of Transcription Factors 
The ZEB family of transcription factors have been implicated in various 
biological processes in development, wound healing and cancer progression.  
Specifically, the ZEB family of proteins plays a role in tumor invasiveness and metastasis 
as well as increased resistance to chemotherapy (Sanchez-Tillo, Siles et al. 2011).   
 The superfamily of zinc finger and homeodomain transcription factors is 
represented in all animals.  In Drosophila, Zfh-1 represents the mammalian ZEB 
superfamily, and Drosophila Zfh2 represents ATBF1, Zfh4, ZFh5, subfamily (Miyoshi, 
Maruhashi et al. 2006).  In humans, the ZEB family contains two members, ZEB1 and 
ZEB2.  Both of these proteins are also known by other names.  ZEB1 for instance is also 
referred to as δEF1, AREB6, BZP, MEB1, Nil-2-a, TCF8, ZEB, ZEB-1, Zfhep1, and 
Zfhx1a.  ZEB2 is also referred to as KIA0569, SIP1, SMAIDIP-1, ZEB-2, and Zfhx1b 
(Peinado, Olmeda et al. 2007).  Both ZEB1 and ZEB2 contain two clusters of zinc fingers 
that are located at the N-terminus and C-terminus; between these zinc fingers is a 
homeodomain (Gheldof, Hulpiau et al. 2012).  ZEB1 and ZEB2 are highly homologous 
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and are required for cell migration during embryonic development. Figure 1 shows the 
domain structures of ZEB1 and ZEB2.  Both ZEB1 and ZEB2 bind to an identical 
consensus DNA sequence (CACCT) and when they are bound to this consensus 
sequence, they typically act as transcriptional repressors (Miyoshi, Maruhashi et al. 
2006).  This binding involves only the zinc fingers, and not the centrally located 
homeodomain (Furusawa, Moribe et al. 1999).  The way in which they can act as 
transcriptional repressors involves the binding of a co-repressor, C-terminal binding 
protein (CtBP).  CtBPs have been shown to act as transcriptional repressors in 
conjunction with the ZEB family of transcription factors (Peinado, Olmeda et al. 2007).   
 Human ZEB1 and ZEB2 have very similar amino acid sequences in their ZF 
domains and homeodomain, but not other areas.  In addition to the zinc finger clusters 
and homeodomain both ZEB proteins have a Smad-interacting domain.  ZEB1 and ZEB2 
require co-factors in order to be fully active.  The presence of the CtBP interacting 
domain allows them to bind CtBP cofactors.  They both target similar gene sequences 
and act to repress the expression of epithelial genes such as E-cadherin (Bracken, 
Gregory et al. 2008).  In humans, both ZEB1 and ZEB2 are 43% homologous (Gheldof, 
Hulpiau et al. 2012).  Expression of ZEB1 and ZEB2 have both been implicated in the 
poor progression of different carcinomas.   
ZEB1 specifically can promote cell migration and metastasis through EMT; 
furthermore ZEB1 endows tumor cells with resistance to radiotherapy independent of 
EMT (Zhang, Sun et al. 2015).  The expression of ZEB1 is controlled by many different 
signaling pathways including TGF-β, Wnt, and notch.  Additionally, its expression is also 
regulated by microRNAS.  ZEB1 can either be a transcriptional activator or a 
11	
transcriptional repressor.  If ZEB1 interacts with the transcriptional co-activators 
p300/CBP-associated factor, ZEB1 will become a transcriptional activator (Lamouille, 
Xu et al. 2014) (Nishimura, Manabe et al. 2006).  Conversely, interaction with the co-
repressor CtBP1 leads to inhibition of transcription of the target gene. ZEB1 expression is 
induced by the TGF-β pathway, where it is a critical effector of TGF-beta signaling, as 
well as the Wnt pathway. ZEB1 expression is also induced by progesterone, loss of which 
is critical for the onset of parturition since ZEB1 represses the oxytocin gene, hence the 
fall of progesterone decreasing ZEB1 causes the spike of oxytocin which induces birth 
(Williams, Renthal et al. 2012).  ZEB1 is also induced by growth factors that are 
responsible for activating the RAS and MAPK pathways. The phosphorylation status of 
ZEB1 is variable in vivo and therefore may be a target of this pathway (Llorens, 
Lorenzatti et al. 2016).   ZEB1 expression has been observed to be expressed in both 
cancer and stromal cells (Bronsert, Kohler et al. 2014).  In a mouse model, the 
overexpression of ZEB1 resulted in the suppression of E-cadherin (Liu, El-Naggar et al. 
2008).  Additionally, ZEB1 also acts as a transcriptional activator of smooth muscle actin 
and myosin, certain collagens, and vimentin. Vimentin is found to be up-regulated in 
many different kinds of epithelial carcinomas (Satelli and Li 2011).   
ZEB1 is also influenced by p53; it has been shown experimentally that when p53 
is knocked out, there is an increase in N-cadherin, ZEB1 and BMI1 as well as reduced 





Figure 1: ZEB1 and ZEB2 domain structures.  ZEB1 and ZEB2 are similar in the fact 
that they both contain two zinc-finger binding domains flanking a central homeodomain.  
Each colored bar on each protein represents a different area; red indicates the zinc finger 
domain, yellow the homeodomain, the purple represents the CtBP binding site, and blue 
represents the Smad interacting domain.  The percentages indicate the percent homology 
between the two transcription factors.  Interactions with different proteins are shown, 




 Developmentally, mutation of ZEB1 leads to secondary palate cleft along with 
other craniofacial abnormalities (Liu, El-Naggar et al. 2008).  During embryonic 
development it is necessary for single cells to detach and invade, specifically in processes 
such as neural crest cell migration; both ZEB1 and ZEB2 play a role in this process 
(Gheldof, Hulpiau et al. 2012).  The ZEB1 null mutant mice survive through embryonic 
development, but apparently die immediately after birth suggesting a defect in the ability 
to breathe (Takagi, Moribe et al. 1998).  ZEB1 knockout mice have also demonstrated 
abnormal corneal epithelium due to the suppression of the epithelial phenotype (Liu, 
Peng et al. 2008).  In humans, a ZEB1 mutation can cause posterior polymorphous 
corneal dystrophy because of aberrant corneal endothelium; this mutation is relatively 
rare and is dominant (Lechner, Dash et al. 2013).  ZEB1 is normally expressed in various 
body tissues including the blood, kidney, eye, and brain and neural crest cells (Kerosuo 
and Bronner-Fraser 2012) (Higashi, Moribe et al. 1997, Takagi, Moribe et al. 1998).  The 
function of ZEB1 is to act as either a transcriptional activator or repressor.  It inhibits the 
expression of the interleukin-2 gene as well as the expression of E-cadherin (Zhang, Tian 
et al. 2014).  It positively regulates neuronal differentiation.  Since it can repress the 
epithelial phenotype, it can promote tumorigenicity by inhibiting microRNAs.   
 On the cellular level, ZEB1 may be phosphorylated by kinases.  This results in 
ZEB1 becoming localized to the cytosol (Llorens, Lorenzatti et al. 2016).  This 
phosphorylation is regulated by growth factors such as IGF-1.  The larger implication of 
this phosphorylation is that it transcriptionally inhibits ZEB1 since it is no longer located 
in the nucleus.   
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ZEB2 is also a member of the ZEB family of transcription factors. It is 1214 
amino acids long and a 140 kDa protein (Grabitz and Duncan 2012). It is a two-handed 
zinc finger homeodomain protein.  As with ZEB1, the homeodomain is flanked by two 
zinc finger clusters; containing either four or three fingers (Figure 1) (Comijn, Berx et 
al.).  The homeodomain is located near the center and it mainly participates in protein-
protein interactions [[Smith + Darling 2003]].  In embryonic development ZEB2 is 
expressed in neural crest cells, neuroepithelium, and limb buds.  ZEB2 knockout mice do 
not survive past 9.5 weeks because the neural tube does not close properly, hence ZEB2 
has essential effects in embryogenesis, whereas ZEB1 is only essential after birth.  ZEB2 
is normally expressed in central nervous tissue, muscle tissue, and hematopoietic cells 
(Comijn, Berx et al.).   
On a subcellular level, ZEB2 interacts with Smads 1,2,3,5, and 8 in its role as an 
effector of the TGF-beta and bone morphogenetic protein (BMP) pathways.  ZEB2 can 
repress the expression of proteins such as claudins, ZO-3, connexins, E-cadherin, 
plakophillin 3, desmoplakin, and crumbs3 (Nam, Lee et al. 2012).  
 ZEB2 aberrations in humans are of consequence.  One such example is Mowat-
Wilson Syndrome which is the result of a missense mutation in the ZEB2 gene 
(Ghoumid, Drevillon et al. 2013).  Mowat-Wilson syndrome is characterized by mental 
retardation, microencephaly, short stature, and a distinctive facial appearance.  ZEB2 is 
normally expressed during embryonic development, neurons, and blood and epithelial 
cells (McKinsey, Lindtner et al. , Korpal, Lee et al. 2008, Tatari, De Craene et al. 2014).  
Elevated ZEB2 levels have also been observed in several types of cancer including: 
breast, ovarian, gastrin, and oral squamous cell carcinoma (Rosivatz, Becker et al. 2002)  
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By binding to the E-cadherin promoter, ZEB2 represses its transcription (Miyoshi, 
Maruhashi et al. 2006).  In addition to suppressing cell adhesion, ZEB2 has also 
demonstrated a protective effect on bladder cancer cells from DNA damage induced 
apoptosis.  In human cell lines, it has been demonstrated that when ZEB2 is 
downregulated then apoptosis is induced by the activation of caspase 3 (Qi, Song et al. 
2012).  Furthermore, in glioma cells, ZEB2 knockdown resulted in normal E-cadherin 
expression and decreasing the vimentin expression.   
The ZEB family contains two closely related transcription factors, however ZEB1 
and ZEB2 are responsible for different functions. For example ZEB1 serves a broad role 
during development by influencing immune cell differentiation, skeletal patterning and 
palate formation (Gheldof, Hulpiau et al. 2012).  Conversely, ZEB2 plays a role in 
maintaining the integrity of the epithelial basement membrane (Tatari, De Craene et al. 
2014).   
Cancer Stem Cells 
OSCC may be especially persistent due to the presence of cancer stem-cells 
(CSCs) (Chu, Hu et al. 2013).  CSCs are an important reason for tumor recurrence, 
progression, and resistance to radiotherapy.  The up-regulation of embryonic stem cell 
genes such as Oct4 and Nanog, indicate that CSC may possess the ability to be 
undifferentiated and therefore produce cancer cells via asymmetrical division.  When 
these  pathways are up-regulated, tumor cells are more likely to persist since they are 
slower growing and therefore more resistant to conventional chemotherapeutic agents 
that target rapidly dividing cells,  The roles of ZEB1 and ZEB2 have not yet been 
understood with respect to the CSC properties of OSCC (Chu, Hu et al. 2013).  The 
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existence of cancer stem cells perpetuates the notion that squamous cell tumors are 
composed of many different types of cells (Schober and Fuchs 2011).  In other words, a 
tumor may not simply be one type of rapidly dividing cell type.  Cancer stem cells are 
able to self-renew and differentiate thereby allowing them to sustain growth.   
 
Tumor Microenvironment  
The tumor microenvironment includes the stroma directly surrounding the tumor; 
it includes many different types of cells that can aid tumor growth and progression (Joyce 
and Fearon 2015).  Tumor cells that are invasive have the ability to influence their 
microenvironment and make a network that is conducive to tumor growth and 
progression (Bauer, Su et al. 2010).  The stroma contains an assortment of cells such as:  
inflammatory cells, endothelial cells, and fibroblasts.  Cancer associated fibroblasts 
(CAF) differ from normal fibroblasts in that they express muscle-specific actin.  How 
CAFs arise is not entirely clear.  It seems as though they arise from fibroblasts that are 
already present in the tissue surrounding the tumor.  TGF-β and PDGF may be the 
paracrine factors responsible for inducing CAFs.  The CAFs that reside in the tumor 
microenvironment are important because they may influence tumor cells directly (Bello, 
Vered et al. 2011).  They have been shown experimentally to be present in the 
microenvironment of many OSCC tumors of the tongue.  In another study they have been 
shown to be facilitators of invasion (Vered, Dayan et al. 2010). Additionally, they secrete 
proteases and enhance the presence of angiogenic factors; all of these facilitate tumor 
progression.  
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ZEB Expression in OSCC  
This project hypothesizes that there are different patterns of expression for the 
transcription factors ZEB1 and ZEB2 in oral squamous cell carcinoma as compared to 
healthy and dysplastic tissue.  Furthermore, the expression patterns of ZEB1 and ZEB2 
will be contrasted in order to get a better understanding of the interplay of these two 
factors in malignant transformation.  The results indicate that there are changes in the 
way that ZEB1 and ZEB2 are expressed in controls and in the different histological 






MATERIALS AND METHODS 
Eighty de-indentified patient biopsy samples fixed in formalin and embedded in 
paraffin were identified by Dr. Brian S. Shumway from the Department of Hospital and 
Surgical Dentistry at the University of Louisville School of Dentistry (IRB: 13.0207).  
The collection comprises 10 samples of each major grade representing fibroma, mild 
dysplasia, moderate dysplasia, severe dysplasia, carcinoma in situ, well differentiated 
carcinoma, moderately differentiated carcinoma, and poorly differentiated carcinoma.   
From each paraffin block, sections were cut at a thickness of five micrometers and 
placed in a deionized distilled water bath at 40o C.  After allowing the sections to float in 
the water for about thirty seconds, they were placed on Fischerbrand Superfrost Plus 
Microscope Slides.  After the sections had properly been seated on the slides they were 
allowed to dry overnight in metal slide holders.  Multiple slides were made for each 
paraffin block.  Cut sections were stored at room temperature in slide boxes until ready to 
use.   
The antibody procedures for these experiments used either a chromogenic 
detection method or a fluorescent detection method.  The procedures for both are similar.  
First, slides were placed in an Autoblot Microhybridization Oven that was pre-heated to a 
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temperature of 58o C, for 30 minutes.  After this time the slides were placed 
directly into mixed xylenes for 15 minutes to remove the melted paraffin.  This was 
repeated twice in different washes of xylenes.  The xylenes are rotated in a manner that 
the third position always contains fresh xylenes at the start of the assay.  After the de-
waxing steps, the slides were then incubated through graded alcohols and phosphate 
buffered saline (PBS) to rehydrate the tissue.   
After rehydration was complete the slides are placed in pre-warmed sodium 
citrate buffer for heat induced epitope retrieval (HIER).  The buffer had been warmed to 
97 0 C in an Autoblot Microhybridization Oven for one hour.  This HIER method 
required the slides to be at this temperature for 30 minutes.  After this step, excess PBS 
on the slides was removed using a Kim-wipe while ensuring that the tissue is not at risk 
for desiccation.  Circles around the tissue were then drawn with a PAP barrier pen to 
prevent reagents from running off the slides.  After the PAP circles were drawn the tissue 
was treated with 3% hydrogen peroxide for five minutes to block any endogenous 
peroxidase activity.  The slides were then washed in 0.1% Triton-PBS for ten minutes in 
a slide box on an Orbital Shaker at speed 3.  After washing, the tissue was blocked with 
normal goat serum (Vectastain ABC Kit, Vector Labs) for one hour.  This again was 
washed for ten minutes prior to the antibody treatment.  The rabbit polyclonal ZEB2 
antibody used in all experiments was obtained from Abcam (Ab 25837) (Table 1).  The 
immunogen for this antibody is within residues 1150 to the C-terminus; this area has low 
sequence similarity and would not result in cross-reactivity with ZEB1.    Upon arrival, 
the antibody was aliquoted and stored at -20o C.  Aliquots were thawed on ice prior to 
use.  The primary antibody was diluted in 4% goat serum.  Dilutions of 1:4000 to 1:5000 
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were used on human tissues and allowed to incubate for two hours at room temperature.  
To ensure that samples did not dry out, the slides were surrounded by wet paper towels 
and covered to provide sufficient humidity.   
 After the primary antibody incubation, the slides were washed in three ten minute 
washes of 0.1% Triton-PBS.  After the washes, the biotinylated secondary antibody 
(prepared per manufacturer’s directions) from the Vectastain ABC kit was applied and 
allowed to incubate for 30 minutes.  After one 10-minute wash, the ABC reagent from 
the kit was applied and subsequently washed off for ten minutes in 0.1% Triton PBS.  
After this final wash, the DAB Peroxidase (3,3’-diaminobenzidine, Vector Labs) 
chromogenic detector was applied for five minutes and then rinsed off with tap water 
until the water ran clear.   
After the chromogen had been developed, the tissue was placed in deionized 
distilled water for one minute followed by dehydration in graded alcohols and xylenes.  
Slides were then mounted in Permount and coverslipped.  After allowing the Permount to 
set, the slides were viewed using a Zeiss Axiocam MRc5 microscope (in the laboratory of 
Dr. Lisa Sandell).  Slides were stored in slide boxes at room temperature.  
In order to dual-label the cancer samples, a fluorescent labelled secondary 
antibody was used.  The additional antibody was for pan-cytokeratin which allowed 
identification of cells of epithelial origin.  For fluorescent antibody labelling the 
procedure following epitope retrieval was slightly altered.  Fluorescent antibody labelling 
does not require treatment with hydrogen peroxide.  After epitope retrieval the tissue was 
blocked for one hour with 10% normal goat serum.  The ZEB2 antibody (Abcam, Ab 
25837) was diluted to a concentration of 1:100 and allowed to incubate at room 
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temperature for two hours.  Along with the ZEB2 antibody, the antibody for 
Pancytokeratin (Thermo Fischer MA1-8204, 1:500) was applied.  After three ten-minute 
washes, the fluorescent secondary for ZEB2 (Alexa Fluor 488 goat anti-rabbit, 1:500) 
was applied for one hour in the dark at room temperature along with that for 
Pancytokeratin (Alexa Fluor 547 goat anti-mouse, 1:500).  The slides were then washed 
in 0.1% Triton-PBS for 10 minutes.  DAPI for nuclear staining (1:2000) was applied for 
five minutes and then washed once for 10 minutes with 0.1% Triton-PBS and once for 10 
minutes with PBS.  The slides were then mounted with VectaMount (Vector Labs) and 
coverslipped.  The tissue was visualized with the Zeiss Axiocam MRc5 fluorescence 
microscope.  Visualization was time sensitive due to the nature of fluorescent antibody 
labelling.  Slides were stored in slide boxes in the 40 C refrigerator. 
 The fluorescent staining procedure outlined above was also implemented for the 
ZEB1 antibody (1:2000, Novus, NBP1-88845) raised against the central homeodomain-
like region.  A BLAST analysis was done in order to avoid cross reactivity with ZEB2.  
Samples were dual stained for ZEB1 and Pan-cytokeratin (same as above) and the same 










Table 1:  Antibodies Used 
Antibody Type of 
Antibody 















































In order to properly assess the epithelial tissues, some distinctions must be made 
regarding the structure of the oral epithelium.  Histologically speaking, the tongue 
epithelium is keratinized stratified squamous epithelium (Bradley, Budnick et al. 2006).  
The architecture of the epithelium consists of a basal layer, a spinous layer, a spinous 
layer, and a granular layer (see Figure 2).  The basal layer is adjacent to the basal lamina 
and stroma, and is where cells are proliferating.  As cells become more differentiated they 
become more superficial. Eventually, the upper layers become enucleated and 
keratinized.     
The tissue was scored for ZEB2 staining intensity as either negative = 0, weak = 
1, moderate = 2, or strong = 3.  Since the pattern of ZEB2 staining was not strictly based 
on simply presence or absence, a qualitative assessment needed to be made in addition to 
intensity.  The location, nuclear or cytosolic, is also a factor that was included in order to 
assess the expression pattern of ZEB2.  Furthermore, scoring recorded whether or not the 
expression was restricted to a particular area or found throughout the epithelial layers.  
The latter was described as ubiquitous whereas the former was described as restricted 
basal, restricted spinous, or restricted granular layer (Woolgar 2006). Furthermore, the 
proportion of cells staining was quantified as 0 if less than 25% of cells were stained 
within the epithelum, 1 if 25-50% were stained, 2 if 50-75% were stained, and 3 if over 








Figure 2:  Epithelial tissue layers.  The stratum basale is the layer in which stem cells 
reside and this is where cells are actively dividing.  As the cells go from the basal layer to 
the stratum corneum they become more differentiated.  The most upper layers may or 
may not be keratinized; this depends on the type of epithelium.  In the oral cavity there 
are both ortho-keratinized and para-keratinized types epithelium.  This project utilizes 
tissues obtained from para- keratinized epithelium.  Figure adapted from Histology & 
Cell Biology:  An Introduction to Pathology (Kierszenbaum and Tres 2015).    
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In the higher grades of carcinoma the epithelial layers became less discernable 
from the surrounding connective tissue and the cancer cells. To ascertain which cells 
were of the epithelial phenotype, the samples were labelled with an antibody for pan-
cytokeratin.  Those cells staining positive for pan-cytokeratin were considered either as 
epithelial cells or epithelial derived cells.  Those that were pan-cytokeratin negative were 
considered stromal immune cells or connective tissue cells.  This helped determine in 
which cells ZEB2 expression was taking place.   
 Once samples were stained they were imaged with either the AxioCam M5c or 
the Leica SP8 confocal microscope.  The AxioCam M5c was used for light microscopy 
and fluorescence.  The confocal microscope allowed sequential fluorescence scanning in 
addition to Z-stacks which allowed greater detail to be observed.   
 
Statistical Analysis 
 In order to assess the differences in expression across the different histological 
grades, the Kruskal-Wallis test for non-parametric ordinal data was utilized.  This test is 
an analysis of variance (ANOVA) for ordinal data.  This was followed by Dunn’s 
Multiple Comparison to identify which individual groups differed.  The analysis was 




There were eight different histological diagnoses were used for ZEB2 and ZEB1 
staining.  The fibroma samples served as the control since fibromas are not considered to 
have pathologic epithelia alterations and generally show normal epithelial maturation.  
The fibroma samples were used to establish the baseline expression.  The pathological 
samples progressed from mild dysplasia, moderate dysplasia, and severe dysplasia, 
carcinoma in situ, to well differentiated carcinoma, moderately differentiated carcinoma, 
and poorly differentiated carcinoma.   
Fibroma 
The ten fibroma samples that were stained for ZEB2 showed positive ZEB2 
staining.  All stained positive for ZEB2 in the nuclei all along the basal layer of 
epithelium.  This is consistent with a role for ZEB2 in relatively undifferentiated 
proliferative cells.  Nine samples displayed a restricted staining pattern, which is defined 
as the presence of ZEB2 in one layer (basal, spinous, or suprabasal).  These samples 
showed strong ZEB2 nuclear staining along the basal layer, with weak cytosolic staining 
of the cells of the spinous layer.  One sample displayed very weak and very restricted 
staining.  Furthermore, the most superficial keratinized layers showed a lack of staining 
for ZEB2 in all ten samples.  The results of ZEB2 immunostaining for each sample is 
described below and summarized in Table 2.		Figure 3 shows a representative sample of 




 All ten samples of fibroma stained positively.  The majority of the cases displayed 
restricted expression with moderate staining through about two-thirds of the length of the 
rete ridges.  This expression pattern was seen in seven cases.  There were no instances of 
negative staining in any of the samples.  Nine of the ten fibroma samples displayed ZEB2 
expression only in the basal and spinous layers.  In the remaining sample, there was only 
very restricted staining in the basal layer.  Overall, the proportion of cells staining 
positively for ZEB2 was quite low.  It should also be noted that in the area below the 
basal lamina, there was strong nuclear ZEB2 staining in the underlying connective tissue.  
These cells are not noticeably fibroblastic in shape, and they are possibly tissue-resident 
immune cells.    
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Table 2: ZEB2 Expression Fibroma Samples Summary  
Sample Cells Location Strength Pattern Proportion 
F1 
 
Basal Nuclear 2 R 
 
0 
Spinous Cytosol 1 
F2 
 
Basal Nuclear 3 R 
 
1 
 Spinous Cytosol 2 
F3 
 
Basal Nuclear 3 R 
 
0 
 Spinous Cytosol 2 
F4 
 
Basal Nuclear 3  
R 
1 
 Spinous Cytosol 2 
F5 
 
Basal Nuclear 1 R 
 
0 
 Spinous Cytosol 2 
F6 Basal Nuclear 1 VR 0 
F7 
 
Basal Nuclear 1 R 0 
 Spinous Cytosol 1 
F8 
 
Basal Nuclear 1 R 0 
 Spinous Cytosol 1 
F9 
 
Basal Nuclear 3 R 1 
Spinous Cytosol 2 
F10 
 
Basal Nuclear 2 R 0 
Spinous Cytosol 1 
Table 2: This table shows all the data collected for the histological grade of fibroma. VR 
indicates a very restricted pattern of staining.  VR is limited to one layer of cells, more 
specifically, the basal cells.  R indicates a restricted pattern.  The R pattern goes beyond 












Figure 3: ZEB2 Expression in Fibroma.  A) Routine power H&E appearance (40X).  
B) DAB stained labelled for ZEB2; grossly the appearance of a band of ZEB2 staining is 
evident in the basal layer.  The pattern is seen consistently in the basal layer of the rete 
ridges.  C) In this 20X image, it clearly shows dark staining nuclei along with some cells 
expressing in the cytosol in the spinous layers.  D)  In this 400X image, there is a clear 
nucleus of the cell surrounded by brown cytosol (black arrow) indicating strong cytosolic 
expression.  This occurs in a few cells and the surrounding cells of the basal layer 




Mild Dysplasia (LDy) 
In nine of the ten samples of mild dysplasia there was positive staining for ZEB2.  
In the samples that did stain, there was a general trend of nuclear staining in the basal 
layer with cytosolic staining apparent in the spinous layer.  For five of the ten mild 
dysplasia samples there was moderate to strong staining in the basal and spinous layers.  
The staining in the basal layer was nuclear while in the spinous the staining was 
cytosolic.   
 Three of the samples display restricted ZEB2 staining, whereas two of the 
samples show ubiquitous staining.  Furthermore, there was one sample that did not stain 
at all for ZEB2. In these samples, ZEB2 stained either in the nucleus only of certain cells, 
the nucleus and cytosol in the same cell, or it did not stain at all.  Most of the samples 
stained both nuclear and cytosolic.  These results are summarized in Table 3 and the most 












Table 3: ZEB2 Expression In Mild Dysplasia  (LDy) 
Sample Cells Location Strength Pattern Proportion 
LDy1 
 
Basal Nuclear 2 R 
 
1 
Spinous Cytosol 1 
LDy2 
 
Basal Nuclear 1 R 
 
2 
 Spinous Cytosol 1 
LDy3 
 
Basal Nuclear 3 R 
 
1 
 Spinous  3 
LDy4 
 






Basal Nuclear 3 R 
 
1 
 Spinous Cytosol 1 
LDy6 Basal Nuclear 2 R 1 
Spinous Cytosol 1 
LDy7 
 
Basal Nuclear 3 R 1 
 Spinous Cytosol 2 
LDy8 
 
Basal Nuclear 2 R 0 
 Spinous Cytosol 1 
LDy9 
 
0     
LDy10 
 
Basal Nuclear 2 R 2 
Spinous Cytosol 2 
Table 3:  This table shows the data collected for mild dysplasia. VR indicates staining to 


















Figure 4: ZEB2 Expression in Mild Dysplasia.  A) In this 200X image there is clear 
nuclear staining in the basal layer as well as scattered cytosolic staining in the spinous 
layer.  B) In this 400X image ZEB2 staining is largely restricted to the nucleus in the 
basal layer.  Adjacent to the rete ridges the underlying connective tissue can be seen.  









Moderate Dysplasia (MDy) 
In moderate dysplasia the samples all stained positively for ZEB2.  The three 
staining patterns that were observed include nuclear only, cytosolic only, and nuclear and 
cytosolic. Five of the ten samples detected ZEB2 in the nucleus in either the basal or 
spinous layers.  There was not any evidence of staining in the upper keratinzed layers.  
The remainder of the samples were stained either only in the cytosol or both nuclear and 
cytosolic.  These data are summarized in Table 4, and Figure 5 shows a representative 




Table 4: ZEB2 Expression Summary Moderate Dysplasia  
Sample Cells Location Strength Pattern Proportion 
MDy1 
 





Basal Nuclear 3 R 
 
2 
 Spinous Cytosol 2 
MDy3 
 
Basal Nuclear 2 R 
 
1 
 Spinous  2 
MDy4 
 
Basal Nuclear 3 R 1 





Basal Nuclear 1 R 
 
1 
 Spinous Cytosol 1 
MDy6 Spinous Cytosol 1 VR 1 
MDy7 
 
Basal Nuclear 3 R 1 
    
MDy8 
 
Basal Nuclear 3 U 2 
 Spinous Cytosol 3 
Keratinized Nuclear 2 
MDy9 
 
Spinous Cytosol 3 VR 1 
MDy10 
 
Basal Nuclear 2 R 2 
Spinous Cytosol 3 
 Keratinized Nuclear 2 
Table 4:		This data for moderate dysplasia are shown in this table.  The VR pattern is restricted 
to the basal layer, R is staining in the basal and spinous layer while U indicates ubiquitous 














Figure 5:  ZEB2 Expression in Moderate Dysplasia.  A) In this low power image there 
is broad, apparently non-specific staining of the DAB, at this magnification it looks as 
though the staining is all over and non-specific.  B)  Higher power shows a more punctate 
pattern, but still not high enough to discern where exactly the staining is occurring.  C) At 
200X the appearance of nuclear staining in the basal layer.  D) There is the appearance of 







ZEB2 Expression Severe Dysplasia 
Moderate dysplasia can progress to severe dysplasia.  The difference between 
moderate and severe dysplasia is the degree of involvement of the epithelial tissue; in 
severe dysplasia over two-thirds of the epithelium displays abnormalities 
(Warnakulasuriya, Reibel et al. 2008).  We had ten samples of severe dysplasia that we 
subjected to antibody staining with ZEB2.   
 Overall, there is a presence of strong cytosolic expression throughout the spinous 
layers.  This pattern was observed in five out of the ten samples.  In one sample there was 
not any presence of ZEB2 staining.  In four of the ten samples there was ZEB2 
expression throughout the thickness of the epithelium and therefore unrestricted.  These 















Table 5:  ZEB2 Expression in Severe Dysplasia Summary 
Sample Cells Location Strength Pattern Proportion 
SDy1 Basal Nuclear 1 R 
 
1 
Spinous Cytosolic 2 
SDy2 
 
Basal Nuclear 2 R 
 
3 
Spinous Cytosolic 3 
SDy3 
 
Basal Nuclear 1 U 
 
3 
 Spinous Cytosolic 3 
 Keratinized Nuclear 2 
SDy4 
 
Spinous Cytosolic 2 R 1 
Keratinized Nuclear 2 
SDy5 
 
  0   
SDy6 Basal Nuclear 1 R 2 
Spinous Cytosolic 2 
SDy7 
 
Basal Nuclear 1 R 2 
Spinous Cytosolic 2 
SDy8 
 
Basal Nuclear 2 U 2 
Spinous Nuclear 3 
Keratinized Nuclear 2 
SDy9 
 
Basal Nuclear 2 R 3 
Spinous Nuclear 2 
SDy10 
 
Basal Nuclear 2 R 3 
Table 5:  Data shown the results for severe dysplasia.  The staining patterns were either 






















Figure 6:  ZEB2 Expression Severe Dysplasia A)  Moderate ZEB2 staining of the 
epithelium and not very frank staining in the underlying connective tissue.  B)  This 
image shows more clearly the appearance of some nuclei in the basal layer staining 
positively for ZEB2; this staining seems limited to the basal layer.  There is also the 
presence of a band of staining in the spinous layer.  C)  The band of staining the spinous 
layer is clearly cytosolic expression (200X).  D)  A higher magnification highlights the 





Carcinoma in Situ (CIS) 
After the severely dysplastic stage, the lesion may progress to carcinoma in situ 
(CIS).  CIS is characterized by the loss of organization in the epithelial tissues 
(Warnakulasuriya, Reibel et al. 2008).  As with the dysplasia samples, there were ten CIS 
samples provided to us and subjected to staining with ZEB2.   
In seven of the ten samples there was unrestricted ZEB2 staining present; the 
pattern of staining was both nuclear and cytosolic.  Of the remaining three, there was one 
instance of negative staining, and two that had restricted staining.  These results are 
summarized in Table 6, and Figure 7 shows a representative sample.  The most striking 
observation in this category as a whole is the presence of a broad band of cytosolic 
staining.  This grade is typified by extensive cytosolic staining in the spinous layer.  
While staining is present in the nuclei of the basal cells adjacent to the connective tissue, 
this is distinctly weaker than in the spinous layers of cells.  This is the first grade with 








Table 6: ZEB2 Expression Summary Carcinoma In Situ 
Sample Cells Location Strength Pattern Proportion 
CIS1 Basal Nuclear 2 R 
 
3 
Spinous Nuclear 2 
CIS2 
 
Basal Nuclear 1 U 
 
3 
 Spinous Cytosolic 2 
Keratinized Nuclear 1 
CIS3 
 
Basal Nuclear 2 U 
 
3 
Spinous Cytosolic 2 
Keratinized Nuclear 2 
CIS4 
 
Basal Nuclear 2 R 2 




Basal Nuclear 3 U 2 
 Spinous Nuclear 2 
Keratinized Nuclear 1 
CIS6 Basal Nuclear 1 R 3 
Spinous Cytosolic 2 
CIS7 
 
  0   
CIS8 
 
Spinous Cytosolic 1 VR 3 
CIS9 
 
Spinous Cytosolic 2 R 3 




Basal Nuclear 1 U 3 
 Spinous Cytosolic 3 
Keratinized Nuclear 1 
Table 6:  This table shows the result for carcinoma in situ.  The three staining patterns 


























Figure 7:  ZEB2 Expression in Carcinoma in Situ.  A) The 200X image on the shows 
one line of nuclei staining positive for ZEB2 in the basal layer. There is also an apparent 
broad band of strong cytosolic expression see in the spinous layer. B) The higher power 




Well Differentiated Carcinoma (WC) 
  The stage after CIS is well differentiated carcinoma.  In this early grade of 
carcinoma, the tissue architecture is not entirely lost and there are certain characteristics 
that are present such as keratin pearls (Kumar, Abbas et al. 2013).  There is a shift in the 
staining pattern of ZEB2 as compared to the dysplasia and CIS samples.  In six of the ten 
well differentiated carcinoma samples there was negative staining for ZEB2.  In the 
remaining four samples there was moderate expression of ZEB2 mostly restricted to 
epithelial tissue.     
 As compared to CIS, there are pronounced changes in ZEB2 expression in well 
differentiated carcinoma.  ZEB2 in most instances was cytosolic and also fewer cells are 
expressing ZEB2.  Furthermore, the expression of ZEB2 was weak to moderate.  
Cytosolic ZEB2 expression was mostly seen in cells at the edges of the keratin pearls.  
ZEB2 positive staining identified a distinct subset of cells closely adjacent to the keratin 
pearls as they are seen on the periphery of the keratin pearls.  These results are 






Table 7:  ZEB2 Expression Summary Well Differentiated Carcinoma 
Sample Strength Location 
WC1 0 N/A 
WC2 0 N/A 
WC3 0 N/A 
WC4 2 Cytosolic+Nuclear 
WC5 0 N/A 
WC6 2 Cytosolic 
WC7  0 N/A 
WC8 0 N/A 
WC9 2 Nuclear 
WC10 2 Nuclear 
Table 7:  Well differentiated staining pattern data shown in this table.  The ZEB2 















Figure 8:  ZEB2 Expression in Well Differentiated Carcinoma.  A) Low power H&E 
showing diagnostic keratin pearls for well differentiated carcinoma.  B) This fluorescent 
stained image (40X) is showing strong cytosolic expression of ZEB2 (green) on the 
periphery of cells showing pan-cytokeratin expression  C) The pan-cytokeratin staining 
(red) confirms that these cells are of epithelial origin.  D) This image is an overlay 






Moderately Differentiated Carcinoma (Mdc) 
 Once the carcinoma has progressed beyond the well differentiated stage, it is 
difficult to discern the layers of the epithelium.  For the grades beyond well differentiated 
carcinoma, the fluorescent staining was more appropriate since it allowed the staining of 
pan-cytokeratin.  One hallmark of carcinoma cells is that they must be pan-cytokeratin 
positive to be considered of epithelial origin.  The pan-cytokeratin was the determining 
factor in which cells were considered to be cancerous, all other cells were considered to 
be stromal cells. Since the organization of the epithelial tissue was no longer intact, it was 
difficult to assign patterns in this grade, as well as in poorly differentiated carcinoma.  
 As the carcinoma loses differentiation in moderately differentiated carcinoma 
cells continued to express ZEB2 in the cytosol, but fewer than 25% of cells were 
expressing ZEB2.  In this grade there was an increased amount of exclusively cytosolic 
expression, as compared to a mixture of nuclear and cytosolic expression.  Cells 
expressed ZEB2 weakly or moderately.  As was observed in well-differentiated 
carcinoma, cells that were expressing ZEB2 were located on the periphery of the keratin 
pearls.  As with well differentiated carcinoma, there were instances of negative ZEB2 
staining; this occurred in half of the samples.  The other half showed nuclear and 
cytosolic staining.  So, overall in this grade, there was decreased number of cells 
expressing ZEB2, and only a rare scattering of cells with nuclear ZEB2 staining.  Table 8 
summarizes these results and Figure 9 shows an example of positively stained ZEB2 




Table 8: ZEB2 Expression Summary in Moderately Differentiated Carcinoma  
Sample Strength Location 
Mdc1 0 N/A 
Mdc2 2 Cytosolic 
Mdc3 0 N/A 
Mdc4 0 N/A 
Mdc6 1 Nuclear + Cytosolic 
Mdc7 0 N/A 
Mdc8 2 Nuclear + Cytosolic 
Mdc9 0 N/A 
Mdc10 1 Nuclear + Cytosolic  
Table 8:  This table show the expression patterns of moderately differentiated carcinoma.  
The location refers to the intracellular location.  Samples that have nuclear and cytosolic 
























Figure 9:  ZEB2 Expression in Moderately Differentiated Carcinoma.  In moderately 
differentiated carcinoma there is a loss of organization as can be seen in the H&E image.  
There was a decreased expression of ZEB2 throughout the samples, those that did stain 





 Poorly Differentiated Carcinoma 
The last stage of carcinoma, poorly differentiated carcinoma, is the most 
disorganized.  In poorly differentiated carcinoma, ZEB2 expression in tumor cells occurs 
either in the nucleus, the cytosol, or a mixture of cells expressing either in the nucleus or 
the cytosol.  Concomitant nuclear and cytosolic expression of ZEB2 was the most 
frequent pattern observed.  The proportion of cells expressing ZEB2 increased to well 
over 50%, and the majority of these cells show nuclear ZEB2 expression.  Hence, the 
transition to this grade includes a broad increase in nuclear ZEB2 expression.  Cells of 
epithelial origin (as labelled by pan-cytokeratin) expressing ZEB2 tended to express 
cytokeratin in lower amounts than those that are not expressing ZEB2; this observation 
had been seen consistently throughout the different grades of carcinoma.  ZEB2 
expression is not only limited to cells of epithelial origin; it is also present in the cells of 
the surrounding stroma.  The results for ZEB2 expression in poorly differentiated 





Table 9: ZEB2 Expression Poorly Differentiated Carcinoma (PC) 
Sample Strength Location 
PC1 2 Nuclear + Cytosolic 
PC2 2 Nuclear + Cytosolic 
PC3 3 Cytosolic 
PC4 0 N/A 
PC5 3 Nuclear + Cytosolic 
PC6 2 Cytosolic 
PC7 2 Nuclear 
PC8 0 N/A 
PC9 3 Nuclear + Cytosolic 
PC10 0 N/A 
Table 9: This table shows the data for poorly differentiated carcinoma ZEB2 staining 
patterns.  Nuclear and cytosolic indicate that cells were expressing ZEB2 in nucleus or in 
















Figure 10:  ZEB2 Expression in Poorly Differentiated Carcinoma. A)  H&E image at 
low power showing tissue disorganization.  B) 40X image displaying epithelial cells with 
positive pan-cytokeratin.  C)  40X ZEB2 (green) showing strong nuclear expression in all 
cells in this field.  D)  DAPI stain to confirm the location of the nuclei.  E)  DAPI and 
ZEB2 overlay confirming that there is both nuclear and cytosolic expression of ZEB2 in 








Using the Prism5 software from GraphPad, the ordinal data were analyzed using the 
Kruskal-Wallis test for non-parametric data (ANOVA), followed by Dunn’s Multiple 
Comparison.  The median of the ZEB2 intensity for each grade was analyzed by Kruskal-
Wallis to see if there were any differences across the data set as a whole.  The Kruskal-
Wallis p-value was 0.0023, indicating significant differences.  This was followed by 
Dunn’s Multiple Comparison to identify which individual groups differed.  The results 
are summarized in Table 10 and Figure 11.  Data show that the expression of ZEB2 is 
higher in CIS than in LDy (p<0.01) or in MDy (p<0.05).  This is readily seen by 
comparing Figure 4A (LDy) and Figure 7A (CIS).       
  
52	
Table 10:  Summary of Dunn’s Multiple Comparison Test for ZEB2 
Histological Grades Compared p-value 
LDy vs. MDy No 
LDy vs. SDy No 
LDy vs. CIS Yes, p<0.01 
MDy vs. SDy No 
MDy vs. CIS Yes, p<0.05 
SDy vs. CIS No 
 
Table 10:  This table compares the scores of the different histological grades with respect 
to their ZEB2 expression levels.  The significance level assigned is p < 0.05.  Based on 
these results there is a statistically significant difference between mild dysplasia and 












Figure 11:  This graph shows the scores for ZEB2 in the different histological grades. 
Data are the median and the interquartile range for N=10 for each grade.  Dunn’s 
Multiple Comparison shows a significant increase of the median in the CIS group.   * 
p<0.05,  ** p<0.01                                   
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ZEB1 Expression  
ZEB1 protein expression varied between healthy tissue, oral epithelial dysplasia, 
CIS, and the different grades of carcinoma.  In histologically normal tissue nuclear ZEB1 
expression was apparent primarily in the basal and spinous layers of the epithelium, with 
scattered cells with nuclear ZEB1 expression in upper regions of the epithelium.  In all 
stages examined, approximately 20% to 30% of cells in the stroma show nuclear ZEB1 
expression.  In dysplasia, the expression of ZEB1 remained in and near the basal layer, 
and was primarily nuclear.  In moderate and severe cases of dysplasia there was nuclear 
expression of ZEB1 near the basal layer in addition to a few cells with cytosolic 
expression in the spinous layer.   
 In samples diagnosed as carcinoma in situ, expression of ZEB1 was strongly 
expanded and observed throughout the thickness of the epithelium.  The number of cells 
expressing ZEB1 increased as compared to dysplasia and the expression was 
predominantly nuclear.  However, the level of expression of ZEB1 was weak to moderate 
in CIS samples.  All CIS samples expressed ZEB1 and the staining patterns are outlined 
in Table 10.   
 ZEB1 expression in well differentiated carcinoma expression varied between the 
patients.  In each sample, most of the expression of ZEB1 was located in and surrounding 
the characteristic keratin pearls.  The samples varied in the number of cells expressing 
ZEB1 from 25% to over 75% of cells.  ZEB1 expression was apparent in cells expressing 
pan-cytokeratin as well as a subset of cells in the surrounding stroma.  The intensity of 
expression of ZEB1 was moderate to strong.  In addition, in epithelium not associated 
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with a keratin pearl, discrete areas of cytosolic ZEB1 expression were identified in cells 
adjacent to the stroma.  This may indicate a change in signaling from the stroma.    
In moderately differentiated carcinoma, the subcellular location of ZEB1 varied 
the most among one single grade.  There were three different subsets that were apparent 
with equal frequency:  nuclear, cytosolic, or both nuclear and cytosolic.  Additionally, the 
proportion of cells expressing ZEB1 also varied among the different samples.  Anywhere 
from 25% to over 75% of cells express ZEB1.  Despite these differences all the samples 
displayed moderate expression of ZEB1.   
 Poorly differentiated carcinoma expressed ZEB1 either in the nucleus of certain 
cells, or in the cytosol of other cells.  The proportion of tumor cells that expressed ZEB 
was also well over 50% of cells in all samples.  The staining intensity for ZEB1 was 
weak to moderate.  Of all the grades studied, the most abundant ZEB1 expression was 
observed in the most advanced carcinomas while early carcinoma expressed it in lower 
amounts; specifically, the proportion of cells expressing ZEB1 was higher in poorly 
differentiated carcinoma.  There was a shift in ZEB1 expression from only nuclear in 
healthy tissue to a mixture of cells with nuclear or cytosolic in carcinoma.  The patterns 
of expression of ZEB1 protein are summarized in Table 9 to show the proportion of 
biopsies with nuclear or cytosolic expression of ZEB1 for each of the different grades. 
This shows that the subcellular location of ZEB1 progresses from predominantly nuclear 
in dysplasia and CIS to heavily cytosolic in the most advanced stage of carcinoma.  The 




Table 11 ZEB1 Expression Summary  
Grade Negative Nuclear Nuclear + 
Cytosolic 
Cytosolic 
Carcinoma In Situ 0/10 7/10 3/10 0/10 
Well differentiated 
Carcinoma 
1/10 6/10 1/10 2/10 
Moderately Differentiated 
Carcinoma 
0/9 3/9 3/9 3/9 
Poorly Differentiated 
Carcinoma 
0/9 4/10 1/10 5/10 
 
Table 11:  This table shows all the data for ZEB1 expression in carcinoma in situ, well 
differentiated carcinoma, moderately differentiated carcinoma, and poorly differentiated 












Figure 12:  ZEB1 Expression.  A) Low power well-differentiated carcinoma showing 
characteristic keratin pearls B) 20X Pan-cytokeratin indicating cells of epithelial origin, 
ZEB1 is expressed in the cytosol of the cells that are on the periphery of the tumor 
islands (indicated by T) C) High power DAPI merge with ZEB1 expression in the 
cytosol, indicated by the yellow arrows D) ZEB1 expression in moderately differentiated 
carcinoma, the expression is spread throughout the cancer sample E) Higher power image 
of ZEB1 and Pan-cytokeratin confirming tumor cells F) DAPI and ZEB1 merge 
indicating the cytosolic expression of ZEB1, indicated by the yellow arrows H) Poorly 
differentiated carcinoma with abundant nuclear ZEB1 expression in the stroma and 
minimal cytosolic expression in the tumor cells I) Pan-cytokeratin identifying tumor cells 
with ZEB1 expression in both the tumor cells and adjacent stroma J) ZEB1 expression in 



























Figure 13: A) In this sample of poorly differentiated carcinoma the epithelial tissue 
adjacent to  the tumor shows ZEB1 nuclear expression  and  cytosolic expression of 
ZEB1 in the tumor itself.   B) The ZEB2 expresion in the epithelial tissue is   cytosolic 







 ZEB1 and ZEB2 have distinct roles and different expression patterns during 
embryonic development. They are expressed in non-overlapping tissue domains in most 
regions, but are co-expressed in neural crest cells and the ventricular zone of the 
developing brain (Miyoshi, Maruhashi et al. 2006).  ZEB1 has broad developmental 
effects, influencing immune cell differentiation, skeletal patterning, immune 
differentiation, palate formation, and neural crest development (Gheldof, Hulpiau et al. 
2012).  Homozygous ZEB1 knockout mice survive through embryogenesis, being viable 
until shortly after birth.  In humans, heterozygous ZEB1 mutation leads to posterior 
polymorphous corneal dystrophy, involving metaplasia and overgrowth of corneal 
endothelial cells (Liskova, Tuft et al. 2007).  In contrast, ZEB2 knockout mice do not live 
past embryonic day 8.5 (Miyoshi, Maruhashi et al. 2006); and in humans, a heterozygous 
mutation in ZEB2 results in Mowat-Wilson syndrome which is characterized by mental 
retardation, microcephaly, short stature and a distinctive facial appearance (Fang, Zeng et 
al. 2014).  Despite their distinct developmental roles, they apparently have similar 
molecular roles in cancer.  Both ZEB1 and ZEB2 are associated with cancer progression 
and metastasis, especially the process of EMT (Vandewalle, Van Roy et al. 2009).  ZEBs 
cause EMT by direct regulation of E-cadherin, vimentin, and other effector genes 
(Lamouille, Xu et al. 2014).  In addition, each ZEB contributes to cancer stem cell 
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generation by inhibiting key microRNAs (Wellner, Schubert et al. 2009) (Polytarchou, 
Iliopoulos et al. 2012).  Enhancement of the EMT-associated stemness phenotype by 
ZEB1 or ZEB2 also causes increased drug- and radio-resistance of tumors  
(Siebzehnrubl, Silver et al. 2013) (Sayan, Griffiths et al. 2009) (Fang, Zeng et al. 2014), 
and disruption of the ZEB1/miR203 pathway is being investigated as a therapeutic 
approach to re-sensitize tumors (Meidhof, Brabletz et al. 2015).  These molecular effects 
are likely the basis for the observations that ZEB1 or ZEB2 is strongly expressed at the 
aggressive front of tumors and their expression correlates with a poorer prognosis for 
several cancers (Brabletz and Brabletz 2010, Fang, Zeng et al. 2014).  However, the role 
of ZEBs in oral squamous cell carcinoma has been less studied than other cancers (Chen, 
Zimmermann et al. 2013).  ZEB1 and ZEB2 mRNA levels have been linked with poorer 
prognosis in head and neck cancer (Chu, Hu et al. 2013), however, protein expression and 
comparison of these two genes at the protein level was not examined.  ZEB expression 
has been related to tumor initiation of several cancers such as lung, pancreatic, and also 
including OSCC  (Chu, Hu et al. 2013).  Therefore, we examined the expression and 
subcellular location of ZEB1 and ZEB2 during the early grades leading to oral squamous 
cell carcinoma with the aim of evaluating its utility as a biomarker.   
In this study, ZEB1 protein expression varied between healthy tissue, oral 
epithelial dysplasia, CIS, and the different grades of carcinoma.  In histologically normal 
epithelium, ZEB1 expression was apparent primarily in nuclei of basal and spinous layers 
of the epithelium, with scattered cells having nuclear ZEB1 expression in upper regions 
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of the epithelium.  This pattern suggests that ZEB1 expression decreases or is lost in most 
of the cells as they progress through differentiation into a keratinized epithelial cells.  
This is consistent with ZEB1 often being associated with more undifferentiated 
progenitor-like cells.  This has been demonstrated with ZEB1 knockdown in cancer cells 
displaying a more epithelial, differentiated phenotype (Brabletz, Bajdak et al. 2011).  In 
dysplasia the expression of ZEB1 remained in and near the basal layer, and was primarily 
nuclear.  In moderate and severe cases of dysplasia there was nuclear expression of ZEB1 
near the basal layer in addition to some cytosolic expression in the spinous layer.  In 
samples diagnosed as carcinoma in situ, expression of ZEB1 was observed throughout 
the thickness of the epithelium.  The number of cells expressing ZEB1 clearly increased 
as compared to dysplasia, however the expression remained predominantly nuclear.  The 
level of expression of ZEB1 was weak to moderate in CIS samples.  The broad 
expression of ZEB1 observed in CIS, along with histological appearance, may render 
ZEB1 a useful marker for CIS.  In addition to the epithelial cells there was also ZEB1 
nuclear expression seen in the surrounding stromal cells.  These cells did not stain 
positively for pan-cytokeratin therefore indicating they are not epithelial cells.  These 
cells are components of the underlying connective tissue, but which types of cells has not 
been ascertained.  Since similar cells are observed in histologically normal tissue, these 
ZEB1+ cells may reflect normal expression of ZEB1 in immune cells and/or a subset of 
fibroblasts.  The presence of ZEB1 in these stromal cells may indicate some role 
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influencing the tumor microenvironment, however clear changes in stromal ZEB1 
expression were not observed in different grades of cancer.           
ZEB1 expression in well differentiated carcinoma varied between the patients.  In 
each sample, most of the expression of ZEB1 was located in and surrounding the 
characteristic keratin pearls.  The samples varied in the number of cells expressing ZEB1 
from 25% to over 75% of cells.  ZEB1 expression was apparent in cells expressing pan-
cytokeratin as well as a subset of cells in the surrounding stroma.  The intensity of 
expression of ZEB1 was moderate to strong.  In addition, in epithelium not associated 
with a keratin pearl, discrete areas of cytosolic ZEB1 expression were identified in cells 
adjacent to the stroma.  This may indicate a change in signaling from the stroma.  In 
addition, it would be of interest to investigate whether the different frequency of ZEB1 
expression in patients correlates with different clinical outcomes.    
In moderately differentiated carcinoma, the subcellular location of ZEB1 varied 
the most among one single grade.  There were three different subsets that were observed 
with equal frequency:  nuclear, cytosolic, or both nuclear and cytosolic. The nuclear and 
cytosolic expression pattern means that some cells were expressing both in the nucleus 
and cytosol or it was nuclear in some cells and cytosolic in others.  Additionally, the 
proportion of cells expressing ZEB1 also varied among the different samples.  Anywhere 
from 25% to over 75% of cells express ZEB1.  Despite these differences all the samples 
displayed moderate expression of ZEB1.  Overall, there was a marked increase in the 
expression of ZEB1 in moderately differentiated carcinoma.   
Poorly differentiated carcinoma samples expressed ZEB1 either in the nucleus of 
certain cells, or in the cytosol of other cells.  The proportion of tumor cells that expressed 
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ZEB was well over 50% of cells in all samples.  The staining intensity for ZEB1 was 
weak to moderate.  Of all the carcinoma grades studied, the most abundant ZEB1 
expression was observed in the most advanced carcinomas while early carcinoma 
expressed it in lower amounts.  There was a shift in ZEB1 expression from only nuclear 
in healthy tissue to a mixture of cells with nuclear or cytosolic in carcinoma.  The 
subcellular location of ZEB1 progresses from predominantly nuclear in dysplasia and 
CIS to heavily cytosolic in the most advanced stage of carcinoma.  Importantly, this is the 
first demonstration of a shift from nuclear to cytosolic ZEB1 in different grades of 
cancer.  Phosphorylation of ZEB1 by specific kinase pathways has been shown 
experimentally to cause cytosolic localization (Llorens, Lorenzatti et al. 2016), however, 
this is the first demonstration of a change in localization in vivo.  ZEB1 in the cytosol is 
not able to regulate transcription of target genes, and would be expected to reduce the 
EMT-characteristics of these cells.  This change of signaling may be occurring due to 
changes in the surrounding environment of the cancer cells.  Samples graded as well 
differentiated carcinoma frequently contained areas where groups of basal epithelial cells 
adjacent to the stroma displayed cytosolic ZEB1, suggesting a change in stromal 
signaling.   In the more advanced cancers, the about half the cells were expressing ZEB1 
in the cytosol while the other half showed expression in the nucleus.  This would be 
worthwhile to examine clinical outcomes to see how this pattern may be associated.   
ZEB2 is closely related, but distinctly different from ZEB1 and therefore it is 
worthwhile looking at expression of ZEB2 in addition to ZEB1.  It is also worthwhile to 
compare the two.  Changes of ZEB2 protein expression were also observed between the 
different pathological grades.  These changes were especially evident in comparing 
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dysplasia and carcinoma in situ and also between moderately differentiated carcinoma 
and poorly differentiated carcinoma.  Generally, histologically healthy tissue expressed 
nuclear ZEB2 moderately in the basal layer; however, in the suprabasal layer scattered 
cells express ZEB2 in the cytosol.  Approximately 25-50% of the cells express ZEB2 in 
the epithelium.   
In oral epithelial dysplasia, nuclear ZEB2 expression occurred most frequently in 
the basal layer with a clear band of cytosolic expression in the suprabasal cells; this 
pattern appeared consistently throughout the three grades of dysplasia (mild, moderate, 
severe).  Based on statistical analysis, there were significant differences in the medians of 
the following categories:  mild dysplasia and CIS and moderate dysplasia and CIS.  
These results suggests that the differences between these subsets are more apparent than 
the other categories. The results are summarized in Table 10.   
In samples of CIS, ZEB2 stained overwhelmingly in either the nucleus or the 
cytosol with 70% of the samples staining with the pattern in Figure 7.  ZEB2 positive 
samples stained in a ubiquitous manner with the staining occurring throughout the 
thickness of the epithelium and not restricted to specific areas as observed in dysplasia.  
Nonetheless, many more cells in the spinous layer showed strong cytosolic expression of 
ZEB2 protein.  This is a clear expansion of mid-epithelial cytosolic expression as 
compared to dysplasia samples.   This change in expression may indicate that the cells are 
undergoing phenotypic changes.  Based on the statistical analysis summarized in Table 
10, it was determined that there is a statistically significant difference in expression of 
ZEB2 between mild dysplasia and CIS as well as between moderate dysplasia and CIS.   
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As compared to CIS, there are pronounced changes in ZEB2 expression in well 
differentiated carcinoma.  First of all, ZEB2 was predominantly expressed in the cytosol 
with few instances of nuclear expression.  The number of cells expressing ZEB2 was also 
decreased.  Furthermore, the expression of ZEB2 was weak to moderate.  Cytosolic 
ZEB2 expression was mostly seen in cells at the edges of the keratin pearls.  
In moderately differentiated carcinoma, cells continued to express ZEB2 in the 
cytosol, but fewer than 25% of the cells were expressing ZEB2.  The subcellular location 
remained the same, but there was a decrease in the number of cells expressing ZEB2.  In 
this grade there was almost exclusively cytosolic expression.  Cells expressing ZEB2 did 
so weakly or moderately at best.  As was observed in well-differentiated carcinoma, cells 
that were expressing ZEB2 were located on the periphery of the keratin pearls.  (Figure 
8).   
 In poorly differentiated carcinoma, ZEB2 expression in tumor cells occurs either 
in the nucleus, the cytosol, or a mixture of cells expressing either in the nucleus or the 
cytosol.  Concomitant nuclear and cytosolic expression of ZEB2 was the most prominent 
pattern observed.  The proportion of cells expressing ZEB2 increased to well over 50%.  
Cells of epithelial origin (as labelled by pan-cytokeratin) expressing ZEB2 tended to 
express cytokeratin in lower amounts than those that are not expressing ZEB2; this 
observation had been seen consistently throughout the different grades of carcinoma.  
ZEB2 expression is not only limited to cells of epithelial origin; it is also present in the 
cells of the surrounding stroma.   
 Despite ZEB1 and ZEB2 having overlapping molecular activities their expression 
patterns were distinct throughout oral epithelial dysplasia, CIS, and the different grades 
66	
of squamous cell carcinoma.  In normal tissue, ZEB1 expression occurred only in the 
nucleus, primarily in the basal cell layers, whereas ZEB2 was largely restricted to 
cytosolic expression in the suprabasal layer.  For ZEB1, mildly dysplastic tissue also has 
predominantly nuclear expression with some cytosolic expression evident in more 
moderate and severe dysplasia.  The staining pattern for ZEB2 in all types of dysplasia 
was similar to normal tissue, some nuclear expression in the basal layer with cytosolic in 
the spinous layer.  For CIS, ZEB1 expression was mainly nuclear throughout the 
epithelium.  Conversely, ZEB2 expression was found in the nucleus of some cells, but 
was widely expressed in the cytosol of cells throughout the mid-epithelium.  As the 
carcinoma loses differentiation into moderately differentiated carcinoma ZEB1 continued 
to be expressed in the nucleus or the cytosol whereas ZEB2 was mainly expressed in the 
cytosol.  In the most poorly differentiated cases ZEB2, rather than ZEB1, is 
predominantly expressed in the nucleus.  There does not appear to be any association 
between the expression of ZEB1 and ZEB2 in poorly differentiated carcinoma with 
regards to subcellular location, strength, or distribution.   
 During normal development in the mouse, both ZEB1 and ZEB2 are consistently 
nuclear (Darling, Stearman et al. 2003, Van de Putte, Francis et al. 2007).  Our data show 
that in histologically normal tongue epithelium and during dysplasia ZEB1 is consistently 
expressed in the nucleus of the basal and spinous layers of the epithelium, with sporadic 
expression in cells in higher levels.  In carcinoma in situ the expression of ZEB1 protein 
expands to additional cells throughout the epithelium, and in many samples is present 
throughout the cell.  Well differentiated carcinoma is characterized by keratin pearls; 
these structures are pan-cytokeratin positive and are surrounded by connective tissue 
67	
(Woolgar and Triantafyllou 2011).  In this grade of carcinoma, ZEB1 continues to be 
expressed in the nucleus of cells	in and around the keratin pearls.  However, in two of the 
10 well differentiated carcinomas the ZEB1 expression was strongly cytosolic and 
limited to cells at the edge of the pearls, adjacent to the stroma.  Localized areas of 
epithelium adjacent to the stroma also show strong cytosolic expression, suggestive of 
signaling from the stroma.  This appears to begin a progression of increasingly cytosolic 
localization of ZEB1 protein as the cancer progresses.  In poorly differentiated 
carcinoma, all tumors express ZEB1, with about half the biopsies showing only nuclear 
ZEB1 protein, and half the biopsies having primarily cytosolic ZEB1.  These two subsets 
of nuclear versus cytosolic localization of ZEB1 raise the possibility of different roles of 
this protein in different patients.  Table 12 demonstrates differences in expression of 
ZEB1 and ZEB2 in poorly differentiated carcinoma.   
 ZEB2 is nuclear during development (Van de Putte, Francis et al. 2007).  ZEB2 in 
tongue epithelium is expressed in the nucleus of the basal layer of cells; however we also 
observed a thin band of occasional scattered cells in the suprabasal layer having only 
cytosolic expression of ZEB2.  In samples graded as carcinoma in situ, the strong 
cytosolic expression of ZEB2 protein is greatly expanded to a large proportion of cells 
across the middle of the epithelium.  In well differentiated cancer fewer cells expressed 
ZEB2 and these were restricted to areas adjacent to or between the keratin pearls.  In 
moderately differentiated oral cancer ZEB2 continued to be largely cytosolic.  However, 
in poorly differentiated cancers ZEB2 was commonly expressed in the nucleus of cells.  
Most of these biopsies shows a mixture of cells expressing either nuclear or cytosolic 
ZEB2.   
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 While ZEB1 has never previously been characterized as being cytosolic, there are 
some instances of ZEB2 in the cytosol (Oztas, Avci et al. 2010, Yang, Sun et al. 2015).  
In a tissue array of advanced cancers, ZEB2/SIP1 was overexpressed in the cytosol of 
cancers of the kidney, breast, lung and uterus (Oztas, Avci et al. 2010). Importantly, in 
colon cancer and cholangiocarcinoma ZEB2 was almost exclusively cytosolic and yet 
expression correlated with tumor stage and patient survival (Kahlert, Lahes et al. 2011), 
or metastasis (Techasen, Loilome et al. 2014).  These results are consistent with our 
observation of cytosolic ZEB2 in OSCC, and importantly indicate that even in the cytosol 
ZEB2 may have clinically significant effects.  Nonetheless, in the most severe grade of 
OSCC we typically observed a mix of cells with cytosolic or nuclear ZEB2.   
 The presence of ZEB1 and ZEB2 in the cytosol of specific cells implies a 
molecular mechanism for regulating the subcellular distribution of ZEBs.  Two 
functionally related EMT-TFs, Snail and Twist, are regulated in part by phosphorylation 
which directly shifts nuclear localization (Lamouille, Xu et al. 2014).  Unlike ZEB2, high 
expression of Snail1 in the nucleus, but not cytosol, is significantly related to a worse 
patient survival in nasopharyngeal carcinoma (Luo, Fang et al. 2012) (Sánchez-Tilló, Liu 
et al. 2012). We have identified nuclear localization signal sequences in ZEB1 and find 
that phosphorylation of adjacent S/T sites can regulate subcellular localization and 
function (Llorens, Lorenzatti et al. 2016).  Whatever the mechanism, exclusion from the 
nucleus may be a means to repress transcriptional regulation by ZEBs.  In addition, ZEBs 
may have unknown molecular functions in the cytosol.   
  The TGF-β pathway is a part of EMT during wound-healing (Lamouille, Xu et 
al. 2014).  It is also been well established that TGF-β protein and mRNA levels are 
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elevated in many different cancers such as breast, lung, prostrate, and stomach cancers 
(Gold 1998).  By repressing E-cadherin and initiating EMT, both ZEB1 and ZEB2 have 
been shown to enhance the effects of TGF-β (Peinado, Olmeda et al. 2007).  In a study 
using Madine-Darby canine kidney cells, it has been demonstrated that exogenously 
elevated levels of TGF-β increase the level of expression of both ZEB1 and ZEB2; the 
implication of this being that TGF-β is promoting an mesenchymal phenotype and that 
phenotype is maintained by elevated levels of ZEB1 and ZEB2 (Gregory, Bracken et al. 
2011).  Additionally, when ZEB1 and ZEB2 levels were decreased by using siRNA, miR-
200a, or miR-200b the cells were able to revert back to an epithelial phenotype.  Though 
both ZEB1 and ZEB2 are part of the TGF-β pathway via Smad interaction, they both act 
in different ways; ZEB1 activates transcription while ZEB2 inhibits transcription (Postigo 
2003).  The differences in expression patterns that were detected in this study may be 
explained by this observation; there are different expression patterns for both ZEB1 and 
ZEB2 in the various stages of carcinoma. Overall, they are both helping to maintain a 








Major Observations    
1. ZEB1 is nuclear in the normal basal cell layer, and can be shifted to cytosolic 
localization in later pathological grades in oral cancer.  
2.  The proportion of cells expressing ZEB1 increases with increasing pathological grade 
in OSCC.  In poorly differentiated carcinoma, all tumors express ZEB1, with about half 
the biopsies showing only nuclear ZEB1 protein, and half the biopsies having primarily 
cytosolic ZEB1.     
3.  Histologically healthy tissue expressed nuclear ZEB2 in the basal layer; however, in 
the suprabasal layer some cells express ZEB2 in the cytosol.    
4. In carcinoma in situ, the strong cytosolic expression of ZEB2 protein is greatly 
expanded to a large proportion of cells across the middle of the epithelium.    
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Future Directions 
The data gathered in this study reveals that there are many different possibilities 
to explore regarding the transcription factors ZEB1 and ZEB2.  EMT is an interesting 
aspect of cancer biology that should be further explored.  One of the limitations of this 
study was the fact that patient survival data, HPV, and smoking status were unknown.  It 
would be beneficial to acquire other data sets that would allow the opportunity to explore 
this information and to see if correlations exist between ZEB expression and localization 
with the aforementioned clinical parameters.  Furthermore, it would be interesting to see 
what the expression of ZEB factors would be in regional lymph nodes in cases of 
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